{"createdAt":"8/2/2020, 2:35:59 PM","timestamp":1596393359086,"Company ID number":"635","DMX_ISSUER_NAME":"SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED","DMX_ISSUER_ID":"IID000000002132463","Country of Classification":"CHINA","name":"Shandong Xinhua Pharmaceutical Co Ltd ","code":"000756","stock_exchange":"Shenzhen Stock Exchange","people":[{"id":"山东新华制药股份有限公司_张代铭","group":"board","name":"张代铭","title":"董事长,执行董事","isMale":true,"age":"58","degree":"硕士","salary":"134.7万","stockAmount":"1.547万","description":"张代铭先生,高级经济师,毕业于青岛科技大学有机化工专业,上海财经大学经济学硕士。1987年到山东新华制药厂工作,历任车间技术员,计划统计处综合计划员,国际贸易部副经理、经理,湖南发展集团股份有限公司副总经理。现任湖南发展集团股份有限公司董事长,山东新华医药集团有限责任公司董事长,山东新华制药进出口有限责任公司执行董事,山东新华制药(欧洲)有限公司董事长,淄博新华-中西制药有限责任公司董事长,淄博新华-百利高制药有限公司董事长,新华(淄博)置业有限公司董事长,山东新华制药(美国)有限责任公司董事长、山东淄博新达制药有限公司董事长。","lastUpdated":"2017-12-23"},{"id":"山东新华制药股份有限公司_杜德平","group":"board","name":"杜德平","title":"执行董事","isMale":true,"age":"51","degree":"硕士","salary":"100.8万","stockAmount":"-","description":"杜德平先生,高级工程师,毕业于中国海洋大学化学专业,山东大学药物化学硕士。1991年到山东新华制药厂工作,历任车间副主任、主任,总经理助理,副总经理。现任湖南发展集团股份有限公司董事、总经理,山东新华医药化工设计有限公司董事长,新华制药(寿光)有限公司董事长。","lastUpdated":"2017-12-23"},{"id":"山东新华制药股份有限公司_任福龙","group":"board","name":"任福龙","title":"非执行董事","isMale":true,"age":"58","degree":"硕士","salary":"96.39万","stockAmount":"-","description":"任福龙先生,研究员、执业药师,1985年毕业于山东昌潍医学院医学专业。1985年至1988年任住院医师。1991年获得北京医科大学医学硕士学位,同年到山东新华制药厂工作,历任研究院副院长、院长,湖南发展集团股份有限公司总经理助理、副总经理,新华医药集团副总经理,湖南发展集团股份有限公司总经理。任先生现任湖南发展集团股份有限公司董事,山东新华医药集团有限责任公司董事、总经理,兼任山东新华万博化工有限公司董事长。","lastUpdated":"2017-12-23"},{"id":"山东新华制药股份有限公司_徐列","group":"board","name":"徐列","title":"非执行董事","isMale":true,"age":"55","degree":"硕士","salary":"85.49万","stockAmount":"-","description":"徐列先生,高级经济师,教授级高级政工师,大学学历,管理学硕士。1986年到山东新华制药厂工作,历任办公室副科长、科长,办公室副主任,人力资源部经理,现任湖南发展集团股份有限公司董事、工会主席,山东新华医药集团有限责任公司董事、工会主席。","lastUpdated":"2017-12-23"},{"id":"山东新华制药股份有限公司_杜冠华","group":"board","name":"杜冠华","title":"独立非执行董事","isMale":true,"age":"64","degree":"博士","salary":"7.000万","stockAmount":"-","description":"杜冠华先生:1956年生,中国国籍,无境外永久居留权,博士研究生学历。1989年毕业于同济医科大学药理学专业,获医学硕士学位;1995年毕业于北京协和医学院,获理学博士学位。自1982年起从事药理学教育和科研工作,1998年至今任职于中国医学科学院药物研究所,历任国家药物筛选中心主任、院校长助理、副所长等职,从事药物发现、高通量药物筛选、神经药理学和心脑血管药理学研究工作,先后主持完成国家科研项目十余项,发表论文多篇,作为第一完成人完成的科研项目“化学药晶型关键技术体系的建立与应用”获得2014年度北京市科学技术奖一等奖;现任中国医学科学院药物研究所副院长、中国药理学会理事长、山西振东制药股份有限公司、河北常山生化药业股份有限公司等公司独立董事,北京昭衍新药研究中心股份有限公司董事,主要参与董事会决策工作。","lastUpdated":"2017-12-23"},{"id":"山东新华制药股份有限公司_李文明","group":"board","name":"李文明","title":"独立非执行董事","isMale":true,"age":"47","degree":"硕士","salary":"7.000万","stockAmount":"-","description":"李文明先生:1973年11月出生,中国国籍,无境外永久居留权,硕士研究生学历、执业药师。曾先后任职于河南省平顶山市湛河区卫生局、北京秦脉医药咨询有限公司、北京北大方正集团公司。现任北京和君咨询有限公司合伙人、深圳和君正德资产管理有限公司合伙人、上海和君投资咨询有限公司副总经理、中国医药商业协会副秘书长、北京爱康宜诚医疗器材有限公司非执行董事、爱康医疗控股有限公司非执行董事、山东新华制药股份有限公司独立董事、南京医药股份有限公司独立董事、云南健之佳健康连锁店股份有限公司董事,2019年4月起任公司独立董事。","lastUpdated":"2017-12-23"},{"id":"山东新华制药股份有限公司_卢华威","group":"board","name":"卢华威","title":"独立非执行董事","isMale":true,"age":"57","degree":"硕士","salary":"7.000万","stockAmount":"-","description":"卢华威先生，于一九八六年毕业于中国香港中文大学,获工商管理学士学位,并于一九九二年毕业于美国新泽西科技学院(New Jersey Institute of Technology),获管理科学硕士学位。卢先生是中国香港会计师公会的执业会员及美国执业会计师公会的会员。卢先生于审核及业务咨询服务方面拥有逾25年服务经验,其中卢先生在一家国际会计师行(德勤·关黄陈方会计师行)的审核及业务咨询服务方面拥有逾7年经验,其中两年曾于美国工作。卢先生现为邦盟汇骏顾问有限公司董事,并兼任联交所主板上市公司重庆机电股份有限公司(股份代号:2722)及天福(开曼)控股有限公司(股份代号:6868)的独立非执行董事。于2009年1月14日获委任为雅天妮集团有限公司公司秘书。卢华威于2014年12月31日担任重庆机电股份有限公司审核委员会主席、薪酬委员会委员。卢华威于2016年3月3日担任重庆机电股份有限公司审核与风险管理委员会主席。","lastUpdated":"2018-06-30"},{"id":"山东新华制药股份有限公司_李天忠","group":"supervisoryCommittee","name":"李天忠","title":"监事会主席","isMale":true,"age":"57","degree":"本科","salary":"83.61万","stockAmount":"-","description":"李天忠先生,高级工程师,1983年毕业于山东工学院工业自动化专业,同年到山东新华制药厂工作,历任电气车间工程师、车间主任、山东新华制药股份有限公司贸易部经理、供销处处长、医药部经理、山东新华制药股份有限公司董事,新华鲁抗药业集团有限责任公司总经理助理、董事、副总经理,山东新华医药集团有限责任公司董事、副总经理。李先生现任为山东新华制药股份有限公司监事会主席,兼任山东新华医药集团有限责任公司副总经理、山东淄博新达制药有限公司董事长。","lastUpdated":"2017-12-23"},{"id":"山东新华制药股份有限公司_陶志超","group":"supervisoryCommittee","name":"陶志超","title":"独立监事","isMale":true,"age":"51","degree":"硕士","salary":"3.000万","stockAmount":"-","description":"陶志超先生,毕业于华东政法学院法律系,获法学学士学位,并取得山东大学法律硕士专业学位。现为山东致公律师事务所合伙人,湖南发展集团股份有限公司独立监事。","lastUpdated":"2017-12-23"},{"id":"山东新华制药股份有限公司_肖方玉","group":"supervisoryCommittee","name":"肖方玉","title":"独立监事","isMale":true,"age":"50","degree":"本科","salary":"3.000万","stockAmount":"-","description":"肖方玉先生,1992年毕业于山东大学数学系,资产评估师、土地估价师。历任山东省淄博市淄川区财政局科员、所长,山东振鲁会计师事务所高级经理,山东北方资产评估事务所部门主任,现任中兴财光华会计师事务所济南分所副所长、天健兴业资产评估有限公司山东公司总经理。","lastUpdated":"2017-12-23"},{"id":"山东新华制药股份有限公司_扈艳华","group":"supervisoryCommittee","name":"扈艳华","title":"职工监事","isMale":false,"age":"46","degree":"硕士","salary":"36.45万","stockAmount":"-","description":"扈艳华女士,毕业于山东大学,研究生学历。一九九六年到山东新华制药股份有限公司工作。历任新华鲁抗药业集团有限责任公司团委副书记,现任山东新华制药股份有限公司政工部部长、团委书记。山东新华制药股份有限公司职工监事。","lastUpdated":"2017-10-31"},{"id":"山东新华制药股份有限公司_王剑平","group":"supervisoryCommittee","name":"王剑平","title":"职工监事","isMale":true,"age":"53","degree":"本科","salary":"25.20万","stockAmount":"-","description":"王剑平先生,毕业于沈阳药科大学化学制药专业,高级工程师,1989年7月加入山东新华制药股份有限公司,历任车间技术员,研究院课题负责人、合成四室主任、药物化学研究中心副主任,现任山东新华制药股份有限公司研究院药物化学研究中心主任、工厂管理委员会职工代表。","lastUpdated":"2017-10-31"},{"id":"山东新华制药股份有限公司_杜德平","group":"manager","name":"杜德平","title":"总经理","isMale":true,"age":"51","degree":"硕士","salary":"100.8万","stockAmount":"-","description":"杜德平先生,高级工程师,毕业于中国海洋大学化学专业,山东大学药物化学硕士。1991年到山东新华制药厂工作,历任车间副主任、主任,总经理助理,副总经理。现任湖南发展集团股份有限公司董事、总经理,山东新华医药化工设计有限公司董事长,新华制药(寿光)有限公司董事长。","lastUpdated":"2017-12-23"},{"id":"山东新华制药股份有限公司_曹长求","group":"manager","name":"曹长求","title":"董事会秘书","isMale":true,"age":"51","degree":"本科","salary":"38.31万","stockAmount":"-","description":"曹长求先生,高级经济师,毕业于中国海洋大学经济管理专业,1991年到山东新华制药厂工作,现任山东新华制药股份有限公司董事会秘书。","lastUpdated":"2017-12-23"},{"id":"山东新华制药股份有限公司_王小龙","group":"manager","name":"王小龙","title":"副总经理","isMale":true,"age":"56","degree":"本科","salary":"87.99万","stockAmount":"-","description":"王小龙先生,高级工程师,毕业于山东工业大学自动化专业,1988年到山东新华制药厂工作,历任电气车间副主任、主任,机械分厂厂长,山东新华制药股份有限公司副总经理,山东新华医药集团有限责任公司副总经理。现任山东新华制药股份有限公司副总经理。","lastUpdated":"2017-12-23"},{"id":"山东新华制药股份有限公司_杜德清","group":"manager","name":"杜德清","title":"副总经理","isMale":true,"age":"56","degree":"博士","salary":"85.99万","stockAmount":"-","description":"杜德清先生,高级工程师,毕业于青岛科技大学有机化工专业,武汉理工大学工商管理及青岛科技大学化学工程双硕士,北京理工大学化学工程与技术学科工学博士。1986年到山东新华制药厂工作,历任调度处科长、副处长、处长,采购物控部经理,总经理助理。现任湖南发展集团股份有限公司副总经理。","lastUpdated":"2017-12-23"},{"id":"山东新华制药股份有限公司_贺同庆","group":"manager","name":"贺同庆","title":"副总经理","isMale":true,"age":"51","degree":"硕士","salary":"87.49万","stockAmount":"-","description":"贺同庆先生,高级经济师,毕业于山东轻工业学院材料科学与工程专业,山东大学工商管理硕士。1991年到山东新华制药厂工作,历任车间技术员、计划员,山东淄博新达制药有限公司销售部业务员、大区经理、新药部经理、营销总监,山东淄博新达制药有限公司总经理。现任湖南发展集团股份有限公司副总经理,山东新华医药贸易有限公司董事长,淄博新华大药店连锁有限公司执行董事,新华制药(高密)有限公司执行董事。","lastUpdated":"2017-12-23"},{"id":"山东新华制药股份有限公司_郑忠辉","group":"manager","name":"郑忠辉","title":"副总经理","isMale":true,"age":"49","degree":"博士","salary":"87.49万","stockAmount":"-","description":"郑忠辉先生,高级工程师,中国协和医科大学微生物与生化药学专业博士研究生。2005年加入湖南发展集团股份有限公司,历任湖南发展集团股份有限公司研究院高级工程师、副院长,现任湖南发展集团股份有限公司副总经理、研究院院长。","lastUpdated":"2017-12-23"},{"id":"山东新华制药股份有限公司_魏长生","group":"manager","name":"魏长生","title":"副总经理","isMale":true,"age":"49","degree":"硕士","salary":"--","stockAmount":"-","description":"魏长生先生,49岁,高级经济师,毕业于江西工业大学食品机械专业,天津财经大学管理学硕士,1992年加入山东新华制药股份有限公司,历任山东新华制药股份有限公司车间见习生,人事处办事员、副科长,车间支部书记兼副主任,研究院支部书记兼副院长,现任山东新华制药股份有限公司总经理助理兼行政人事部经理、党委干部管理部部长、人力资源部经理、党委办公室主任、公司办公室主任。","lastUpdated":"2020-07-02"},{"id":"山东新华制药股份有限公司_徐文辉","group":"manager","name":"徐文辉","title":"副总经理","isMale":true,"age":"44","degree":"","salary":"--","stockAmount":"-","description":"徐文辉先生,44岁,高级工程师,毕业于天津大学化学工程专业。1999年加入山东新华制药股份有限公司,历任山东新华制药股份有限公司车间助理工程师、团委副书记、车间支书兼副主任、新华制药(寿光)有限公司(“寿光公司”)副经理、生产运行部经理。现任山东新华制药股份有限公司总经理助理兼寿光公司经理。","lastUpdated":"2020-07-02"},{"id":"山东新华制药股份有限公司_侯宁","group":"manager","name":"侯宁","title":"财务负责人","isMale":true,"age":"47","degree":"硕士","salary":"83.91万","stockAmount":"-","description":"侯宁先生,中国香港浸会大学应用会计与金融理学硕士,高级会计师、高级经济师。曾任山东华鲁恒升集团审计处副处长,山东华鲁恒升化工股份有限公司审计部部长、技术开发中心投资部部长、市场部经理、财务部经理。现任湖南发展集团股份有限公司财务负责人,淄博新华-百利高制药有限公司董事,山东新华医药贸易有限公司董事。","lastUpdated":"2017-12-23"}],"companyName":"山东新华制药股份有限公司","province":"山东省","englishName":"Shandong Xinhua Pharmaceutical Co","industry":"医药生物 — 化学制药","website":"www.xhzy.com","mainBusiness":"开发、制造和销售化学原料药、制剂及化工产品","productsName":["解热镇痛类原料药","片剂","针剂","胶囊剂","医药中间体"],"actualController":"山东省国有资产监督管理委员会","actualControllerSharePercentage":"22.31%","registeredCapital":"6.22亿元","employeeAmount":"6399","phone":"86-0533-2166666;86-0533-2196024","location":"山东省淄博市张店区高新技术产业开发区鲁泰大道1号","chineseDescription":"山东新华制药股份有限公司主要从事开发、制造和销售化学原料药、制剂、化工及其它产品；公司的主要产品有解热镇痛类原料药、片剂、针剂、胶囊剂、医药中间体。公司拥有技术创新优势,现为高新技术企业、国家火炬计划重点高新技术企业、国家火炬计划生物医药产业基地骨干企业,拥有国家级企业技术中心,建有企业博士后科研工作站。“基于产业化关键技术的咖啡因绿色制备体系构建与规模开发”荣获2018年度山东省科学技术进步二等奖。上半年获得专利授权10件。公司被公示为“山东省技术创新示范企业”，被评为山东人才工作先进单位。","foundedDate":"1993-09-30","goPublicDate":"1997-08-06","companyHistory":"山东新华制药股份有限公司（以下简称本公司，在包含子公司时统称本集团）于1993年由山东新华制药厂改制设立。1996年12月本公司以中国香港为上市地点，公开发行中华人民共和国H股股票。1997年7月本公司以深圳为上市地点，公开发行中华人民共和国A股股票。1998年11月经中华人民共和国对外贸易经济合作部批准后，转为外商投资股份有限公司。2001年9月经批准增发A股普通股票3,000万股，同时减持国有股300万股。\n　　本公司经批准于2017年9月向2名特定投资者非公开发行人民币股票21,040,591股，发行价格人民币11.15元，新增注册资本21,040,591元。\n　　2018年7月，公司实施2017年年度分红方案，资本公积转增股本143,506,026股，转增后公司股本总额为621,859,447股，公司注册资本为人民币621,859,447.00元。\n　　2019年4月3日，本公司控股股东由山东新华医药集团有限责任公司变更为华鲁控股集团有限公司。\n　　截至2019年6月30日，本公司的注册资本为人民币621,859,447.00元。\n　　截至2019年12月31日，本公司的注册资本为人民币621,859,447.00元。收起▲","shareholders":[{"organizationId":"T000056447","holderName":"华鲁控股集团有限公司","totalShare":"2.05亿","sharePercentage":"32.94%"},{"organizationId":"00201544","holderName":"香港中央结算(代理人)有限公司","totalShare":"1.93亿","sharePercentage":"31.04%"},{"organizationId":"","holderName":"巨能资本管理有限公司-山东聚赢产业基金合伙企业(有限合伙)","totalShare":"2331.02万","sharePercentage":"3.75%"},{"organizationId":"","holderName":"齐鲁证券资管-民生银行-齐鲁民生2号集合资产管理计划","totalShare":"864.98万","sharePercentage":"1.39%"},{"organizationId":"","holderName":"黄佩玲","totalShare":"854.12万","sharePercentage":"1.37%"},{"organizationId":"","holderName":"林穗贤","totalShare":"512.99万","sharePercentage":"0.82%"},{"organizationId":"T000125370","holderName":"香港中央结算有限公司","totalShare":"436.71万","sharePercentage":"0.70%"},{"organizationId":"T003843991","holderName":"华鲁投资发展有限公司","totalShare":"414.32万","sharePercentage":"0.67%"},{"organizationId":"","holderName":"山东新华制药股份有限公司-第一期员工持股计划","totalShare":"404.26万","sharePercentage":"0.65%"},{"organizationId":"","holderName":"陈惠芳","totalShare":"133.00万","sharePercentage":"0.21%"}],"englishDescription":"SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED is a China-based company principally engaged in the development, production and distribution of chemical bulk drugs, preparations and medical intermediates. The Company鈥檚 main products include metamizole sodium, caffeine, aminopyrine, aspirin, hydrocortisone, pipemidic acid, ibuprofen, L-dopa, pipemidic acid tablets, compound liquorice tablets and nimodipine tablets. The Company distributes its products in domestic market and to overseas markets, including the Americas, Europe and others.","englishIndustry":"Biotechnology & Drugs","Price to earnings (ttm)":"24.40","Price to sales (ttm)":"1.05","Price to book (mrq)":"3.31","Price to cash flow (ttm)":"--","Total debt to equity (mrq)":"59.89","Lt debt to equity (mrq)":"17.87","Return on investment (ttm)":"8.38","Return on equity (ttm)":"5.12","Income statement":{"Revenue":"5,606.02","Total revenue":"5,606.02","Cost of revenue, total":"3,731.39","Gross profit":"1,874.64","Selling/general/admin. expenses, total":"1,113.75","Research & development":"235.40","Depreciation/amortization":"51.13","Interest exp.(inc.),net-operating, total":"38.49","Unusual expense (income)":"85.32","Other operating expenses, total":"(35.36)","Total operating expense":"5,220.12","Operating income":"385.90","Other, net":"(4.51)","Net income before taxes":"381.39","Provision for income taxes":"58.28","Net income after taxes":"323.12","Minority interest":"(23.15)","Net income before extra. items":"299.97","Net income":"299.97","Income available to com excl extraord":"299.97","Income available to com incl extraord":"299.97","Diluted net income":"299.97","Diluted weighted average shares":"624.93","Diluted eps excluding extraord items":"0.48","Dps - common stock primary issue":"0.12","Diluted normalized eps":"0.60","Gain (loss) on sale of assets":"18.16"},"Balance sheet":{"Cash":"0.08","Cash & equivalents":"578.81","Cash and short term investments":"578.89","Accounts receivable - trade, net":"309.31","Total receivables, net":"533.96","Total inventory":"1,130.34","Prepaid expenses":"73.61","Other current assets, total":"111.58","Total current assets":"2,428.39","Property/plant/equipment, total - gross":"5,453.07","Accumulated depreciation, total":"(2,252.10)","Property/plant/equipment, total - net":"3,200.98","Intangibles, net":"411.59","Long term investments":"369.06","Other long term assets, total":"26.01","Total assets":"6,436.02","Accounts payable":"434.39","Accrued expenses":"94.49","Notes payable/short term debt":"904.12","Current port. of  lt debt/capital leases":"349.00","Other current liabilities, total":"703.51","Total current liabilities":"2,485.51","Long term debt":"589.78","Capital lease obligations":"51.14","Total long term debt":"640.92","Total debt":"1,894.04","Deferred income tax":"53.82","Minority interest":"141.50","Other liabilities, total":"145.24","Total liabilities":"3,467.00","Common stock, total":"621.86","Additional paid-in capital":"634.14","Retained earnings (accumulated deficit)":"1,531.02","Other equity, total":"182.01","Total equity":"2,969.03","Total liabilities & shareholders' equity":"6,436.02","Total common shares outstanding":"816.86","Tangible book value per share, common eq":"3.13"},"Cash flow":{"Cash receipts":"4,864.32","Cash payments":"(2,804.00)","Cash taxes paid":"(187.25)","Changes in working capital":"(1,524.81)","Cash from operating activities":"348.27","Capital expenditures":"(366.51)","Other investing cash flow items, total":"(46.43)","Cash from investing activities":"(412.94)","Financing cash flow items":"(60.63)","Total cash dividends paid":"(116.40)","Issuance (retirement) of debt, net":"130.79","Cash from financing activities":"(46.23)","Foreign exchange effects":"1.28","Net change in cash":"(109.62)"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"12.21","52 Week High":"13.30","52 Week Low":"6.22","Pricing date":"","10 Day Average Trading Volume":"24.87","Market Capitalization":"5,998.39","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"329.58","Beta":"0.81","1 Day Price Change":"0.41","13 Week Price Return (Daily)":"23.46","26 Week Price Return (Daily)":"43.48","5 Day Price Return (Daily)":"1.83","52 Week Price Return (Daily)":"76.45","Year To Date Price Return (Daily)":"62.37","Month to Date Price Return (Daily)":"18.31","Price Relative to S&P500 (4 Week)":"9.13","Price Relative to S&P500 (13 Week)":"-2.94","Price Relative to S&P500 (26 Week)":"12.38","Price Relative to S&P500 (52 Week)":"19.91","Price Relative to S&P500 (YTD)":"24.18"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"0.48","EPS excl. Extra Items (TTM)":"0.50","EPS Normalized (Annual)":"0.60","Revenue per Share (Annual)":"8.97","Revenue per Share (TTM)":"9.16","Book Value (Per Share Annual)":"3.63","Book Value (Per Share Quarterly)":"3.69","Tangible Book Value (Per Share Annual)":"3.13","Tangible Book Value (Per Share Quarterly)":"3.18","Cash Per Share (Per Share Annual)":"0.71","Cash Per Share (Per Share Quarterly)":"1.63","Cash Flow (Per Share Annual)":"1.06","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"0.12","Dividends (Per Share TTM)":"0.12","EBITD (Per Share TTM)":"0.83","EPS Basic excl. Extra Items (Annual)":"0.48","EPS Basic excl. Extra Items (TTM)":"0.50","EPS incl. Extra Items (Annual)":"0.48","EPS incl. Extra Items (TTM)":"0.50","Free Cash Flow (Per Share TTM)":"-0.08","Dividend (Per Share 5Y)":"0.06"},"Valuation":{"P/E excl. Extra Items (Annual)":"25.44","P/E excl. Extra Items (TTM)":"24.40","P/E Normalized (Annual)":"20.50","Price to sales (Annual)":"1.07","Price to sales (TTM)":"1.05","Price to Tangible Book (Annual)":"2.35","Price to Tangible Book (Quarterly)":"2.31","Price to Free Cash Flow (Per Share Annual)":"--","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"--","Price to Book (Annual)":"3.36","Price to Book (Quarterly)":"3.31","P/E Basic excl. Extra Items (TTM)":"24.44","P/E excl. Extra Items High (TTM)":"151.07","P/E excl. Extra Items Low (TTM)":"13.54","P/E incl. Extra Items (TTM)":"24.40","Net Debt (Interim)":"470.86","Net Debt (Annual)":"1,315.15","Dividend Yield (5Y)":"0.68","Dividend Yield":"0.98","Current Dividend Yield (TTM)":"0.98"},"Financial Strength":{"Free Cash Flow (Annual)":"-134.64","Current Ratio (Annual)":"0.98","Net Interest coverage (Annual)":"13.24","Long Term Debt/Equity (Annual)":"21.59","Payout Ratio (Annual)":"24.88","Quick Ratio (Annual)":"0.52","Total Debt/Total Equity (Annual)":"63.79","Current EV/Free Cash Flow (Annual)":"41.66","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"1.25","Long Term Debt/Equity (Quarterly)":"17.87","Quick Ratio (Quarterly)":"0.92","Total Debt/Total Equity (Quarterly)":"59.89","Free Cash Flow (TTM)":"-49.11","Net Interest Coverage (TTM)":"15.01","Payout Ratio (TTM)":"24.01"},"Margins":{"Gross Margin (Annual)":"33.44","Gross Margin (TTM)":"31.29","Net Profit Margin % (Annual)":"5.76","Net Profit Margin (TTM)":"5.88","Operating Margin (Annual)":"6.88","Operating Margin (TTM)":"7.08","Pretax Margin (TTM)":"6.97","Pretax Margin (Annual)":"6.80","Operating Margin (5Y)":"5.37","Pretax Margin (5Y)":"5.48","Free Operating Cash Flow/Revenue (5Y)":"0.09","Free Operating Cash Flow/Revenue (TTM)":"-0.86","Gross Margin (5Y)":"28.55","Net Profit Margin (5Y)":"4.58"},"Management Effectiveness":{"Return on Assets (Annual)":"5.22","Return on Equity (TTM)":"5.12","Return on Average Equity (Annual)":"10.59","Return on Average equity (TTM)":"10.70","Return on Investment (Annual)":"8.88","Return on Investment (TTM)":"8.38","Return on Average Assets (5Y)":"4.08","Return on Average Equity (5Y)":"8.48","Return on Investment (5Y)":"6.95","Asset Turnover (Annual)":"0.91","Asset Turnover (TTM)":"0.87","Inventory Turnover (Annual)":"3.56","Inventory Turnover (TTM)":"4.88","Net Income/Employee (Annual)":"50,660.98","Net Income/Employee (TTM)":"52,312.68","Receivables Turnover (Annual)":"17.18","Receivables Turnover (TTM)":"8.61","Revenue/Employee (Annual)":"878,962.20","Revenue/Employee (TTM)":"889,863.80"},"Growth":{"Revenue Growth (Quarterly YoY)":"4.67","Revenue Growth Rate (5Y)":"9.32","EPS Growth (Quarterly YoY)":"16.67","EPS Growth (TTM YoY)":"18.50","EPS Growth Rate (5Y)":"41.27","Dividend Growth Rate (3Y)":"--","Revenue Growth (TTM YoY)":"4.35","Revenue Growth (Per Share 5Y)":"8.24","Revenue Growth Rate (3Y)":"11.77","EPS Growth Rate (3Y)":"32.64","Book Value Growth Rate (Per Share 5Y)":"3.49","Tangible Book Value Total Equity CAGR (5Y)":"11.15","Capital Spending growth rate 5 year":"7.09","EBITDA CAGR (5Y)":"21.69","EBITDA Interim CAGR (5Y)":"27.91","Free Operating Cash Flow CAGR (5Y)":"--","Total Debt CAGR (5Y)":"3.47","Net Profit Margin Growth Rate (5Y)":"24.80"},"Income Statement":{"Revenue (Annual)":"5,606.02","Revenue (TTM)":"5,694.24","EBITD (Annual)":"848.46","EBITD (TTM)":"516.45","Earnings Before Taxes (Annual)":"381.39","Earnings Before Taxes (TTM)":"397.10","Net Income to Common (Annual)":"299.97","Net Income to Common (TTM)":"310.81","Earnings Before Taxes Normalized (Annual)":"466.71","Net Income Available to Common Normalized (Annual)":"372.25","Diluted Normalized EPS excl. Extra Items (TTM)":"0.62"}}}